FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for Intravenous Use

Dateline City:

WHITEHOUSE STATION, N.J.

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration has approved
NOXAFIL® (posaconazole) injection (18 mg/ mL), a new
formulation of NOXAFIL for intravenous (IV) use. Merck’s antifungal
agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and
NOXAFIL (40 mg/mL) oral suspension.
Language:

English

Contact:

MerckMedia:Pam Eisele, [phone]Robert Consalvo, [phone]orInvestor:Carol Ferguson, [phone]Justin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Product News - March 14, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news